Conditional

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

Retrieved on: 
Jeudi, septembre 21, 2023
Medicine, Kidney failure, International, Heart Protection Study, CMA, Jay Traver, European Medicines Agency, Clinical trial, EGFR, European Directive on Traditional Herbal Medicinal Products, CSL Vifor, Immunoglobulin A, Dialysis, Committee, EMA, Proteinuria, Conditional, Nephrology, ANCOVA, Shanda, Publication, Patient, Division, Risk, Irbesartan, Kidney transplantation, Webcast, Committee for Medicinal Products for Human Use, FDA, Therapy, PROTECT, Kidney disease, Safety, CHMP, Hydraulic machinery, Medical device, Pharmaceutical industry, EU, IgA nephropathy

This outcome is incredibly important for IgAN patients, who face the risk of progression to kidney failure in their lifetime.

Key Points: 
  • This outcome is incredibly important for IgAN patients, who face the risk of progression to kidney failure in their lifetime.
  • “Since our accelerated approval, we’ve continued to hear inspiring stories of the impact this medicine is having on people living with IgAN.
  • While eGFR total slope narrowly missed statistical significance, the overall evidence from PROTECT suggests potential long-term benefit of FILSPARI as a foundational treatment for patients with IgAN.
  • Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.

Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

Retrieved on: 
Jeudi, septembre 21, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Kidney failure, Heart Protection Study, CMA, Jay Traver, European Medicines Agency, EGFR, European Directive on Traditional Herbal Medicinal Products, CSL Vifor, Medicine, Committee, EMA, Proteinuria, Conditional, Shanda, ANCOVA, Publication, Patient, Risk, Irbesartan, Committee for Medicinal Products for Human Use, FDA, Therapy, PROTECT, Kidney disease, Safety, CHMP, Hydraulic machinery, Pharmaceutical industry, EU, IgA nephropathy

This outcome is incredibly important for IgAN patients, who face the risk of progression to kidney failure in their lifetime.

Key Points: 
  • This outcome is incredibly important for IgAN patients, who face the risk of progression to kidney failure in their lifetime.
  • We’re proud of the high bar we’ve set in delivering the only head-to-head study in IgAN, which compares FILSPARI against maximally tolerated dose of irbesartan.
  • Since our accelerated approval, we’ve continued to hear inspiring stories of the impact this medicine is having on people living with IgAN.
  • While eGFR total slope narrowly missed statistical significance, the overall evidence from PROTECT suggest potential long-term benefit of FILSPARI as a foundational treatment for patients with IgAN.

San Juan Basin Royalty Trust Announces PNC Bank, National Association Signs an Agreement of Conditional Resignation with Argent Trust Company

Retrieved on: 
Mardi, septembre 12, 2023
Professional Services, Mining, Minerals, Oil, Gas, Natural Resources, Energy, Finance, Banking, Agreement, PNC, SJT, PNC Financial Services, Trust, Unit, Conditional, Acquisition, BBVA, Trustee, National Association, NYSE, Security (finance), Road transport, Argent

PNC Bank, National Association (“PNC”), as the trustee (the “Trustee”) of the San Juan Basin Royalty Trust (the “Trust”) (NYSE: SJT), announced that it has entered into an Agreement of Conditional Resignation with Argent Trust Company, a Tennessee chartered trust company (“Argent”), pursuant to which the Trustee will be resigning as trustee of the San Juan Basin Royalty Trust, and will nominate Argent as successor trustee.

Key Points: 
  • PNC Bank, National Association (“PNC”), as the trustee (the “Trustee”) of the San Juan Basin Royalty Trust (the “Trust”) (NYSE: SJT), announced that it has entered into an Agreement of Conditional Resignation with Argent Trust Company, a Tennessee chartered trust company (“Argent”), pursuant to which the Trustee will be resigning as trustee of the San Juan Basin Royalty Trust, and will nominate Argent as successor trustee.
  • PNC assumed the administration of the Trust in 2021 through the acquisition of BBVA USA Bancshares, Inc. PNC’s decision to resign is based on its determination that the administration of royalty trusts, such as the Trust, is not part of its long-term strategy.
  • PNC has appreciated the opportunity to serve as Trustee of the San Juan Basin Royalty Trust over the past two years and welcomes collaborating with Argent in the transition as successor trustee.
  • The Trustee’s resignation as Trustee, and Argent’s appointment as successor trustee, are subject to certain conditions set forth in the Agreement of Conditional Resignation, which include the Unit Holders’ appointment of Argent as successor trustee and the approval of any amendments to the San Juan Basin Royalty Trust Indenture necessary to permit Argent to serve as successor trustee.

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Mercredi, septembre 6, 2023
Conditional, Therapy, CAB, Conference, SAN, Pharmaceutical industry

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023.

Key Points: 
  • SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate virtually in scheduled one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, to be held September 11-13, 2023.
  • Date/Time: Pre-recorded presentation available on-demand Monday, September 11, at 7:00 a.m.
  • ET

Switch Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Mercredi, septembre 6, 2023
Oncology, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Conditional, Morgan Stanley, Morgan, Entrepreneurship, Therapy, Conference, RNA, Disease, Pharmaceutical industry

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced that Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a corporate overview at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 10:50 a.m.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced that Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a corporate overview at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 10:50 a.m.
  • ET (7:50 a.m. PT) in New York City.
  • Members of management will also be available for one-on-one meetings.

American Investment Migration Steps Up to Assist EB-5 Investors in Troubled Projects

Retrieved on: 
Jeudi, août 31, 2023
PALM, Conditional, AIM, American Investment Council, EB-5, WEST, NCE, Renewable energy

WEST PALM BEACH, Fla., Aug. 31, 2023 /PRNewswire/ -- American Investment Migration LLC (AIM), a forerunner in the investment migration sector, is pleased to announce the publication of a seminal article titled "After EB-5 Project Failure: Is Permanent Green Card Success Possible?" authored by its partner, Kraig Schwigen.

Key Points: 
  • WEST PALM BEACH, Fla., Aug. 31, 2023 /PRNewswire/ -- American Investment Migration LLC (AIM), a forerunner in the investment migration sector, is pleased to announce the publication of a seminal article titled " After EB-5 Project Failure: Is Permanent Green Card Success Possible? "
  • Some of the points the article covers includes:
    How EB-5 investors can overcome a lack of job creation in their initial EB-5 investment.
  • This proactive move not only facilitates job creation but targets alignment with the primary objectives of the investors.
  • Essential takeaways also include understanding the conditions vital for successful navigation, from retaining the lawful resident status to the judicious selection of new projects.

Top Strike Announces 2023 Fourth Quarter and Annual Financial Results ending April 30, 2023 and Corporate Update

Retrieved on: 
Mardi, août 29, 2023
Treasury, CSE, CGT, CRC, Conversion, TGC, Canadian Advanced Nanospace eXperiment Program, New Jersey Cannabis Regulatory Commission, Conditional, Investment, Gold, BID, Financial result, Transaction, Warrant (finance), Cryptocurrency, Security (finance), Bank

As at April 30, 2023, 53% of the Company's assets and 92% of income was directly related to US cannabis activities.

Key Points: 
  • As at April 30, 2023, 53% of the Company's assets and 92% of income was directly related to US cannabis activities.
  • The Company generated $132,753 (2022 - $123,309) in interest income from its short-term treasury deposits and two receivable notes.
  • Expenses for the three months ended April 30, 2023, were $263,598 (2022 - $308,184).
  • On August 16, 2023, the Company amended and restated its definitive agreement with Cannavative (the "A&R Definitive Agreement" or the "Transaction").

Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Mardi, août 8, 2023
PDAC, Docetaxel, KRAS, American Journal of Clinical Oncology, Marketing, MTA, Pharming, European Medicines Agency, Cholangiocarcinoma, New Drug Application, American Society of Clinical Oncology, SOS1, Cancer Discovery (journal), SAPPHIRE, Cancer, Clinical trial, Committee on Herbal Medicinal Products, Mirati Therapeutics, NSCLC, Cetuximab, TPS, Trial of the century, Committee, EMA, ASCO, Conditional, Shanda, Journal, Outline, Patient, Investment, Manuscript, Meekness, Colorectal cancer, Committee for Medicinal Products for Human Use, Annual general meeting, MAA, Research, FDA, Pembrolizumab, Therapy, Society, Nivolumab, PRMT5, CHMP, Cryptocurrency, Communications satellite, Pharmaceutical industry, Nursing

SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.

Key Points: 
  • ET / 2:30 p.m. PT
    SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.
  • Based on these results, the Company plans to discuss a tumor agnostic Accelerated Approval approach with FDA by year-end 2023.
  • Net reduction in cash, cash equivalents and short-term investments for the second quarter of 2023 was $122.9 million.
  • ET / 2:30 p.m. PT during which company executives will review financial information for the second quarter and provide corporate updates.

BioAtla to Participate in Upcoming Investor Conferences in August

Retrieved on: 
Jeudi, août 3, 2023
Conditional, Therapy, CAB, SAN, Pharmaceutical industry, Consumer electronics

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in two upcoming investor conferences, to be held in August 2023.

Key Points: 
  • SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in two upcoming investor conferences, to be held in August 2023.
  • Please contact your BTIG sales representative to register for the conference.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mirati Therapeutics, Inc. – MRTX

Retrieved on: 
Mercredi, août 2, 2023
LLP, European Directive on Traditional Herbal Medicinal Products, Mirati Therapeutics, NSCLC, Lung cancer, Committee, EMA, Conditional, Patient, Committee for Medicinal Products for Human Use, Mirati, MAA, Indoor Living, Pomerantz, News, CHMP, Private investigator

NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) (NASDAQ: MRTX).

Key Points: 
  • NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc. (“Mirati” or the “Company”) (NASDAQ: MRTX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Mirati and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.